期刊文献+

Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment 被引量:34

Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment
下载PDF
导出
摘要 In patients with inflammatory bowel disease(IBD), chronic inflammation is a major risk factor for the development of gastrointestinal malignancies. The pathogenesis of colitis-associated cancer is distinct from sporadic colorectal carcinoma and the critical molecular mechanisms underlying this process have yet to be elucidated. Patients with IBD have also been shown to be at increased risk of developing extra-intestinal malignancies. Medical therapies that diminish the mucosal inflammatory response represent the foundation of treatment in IBD, and recent evidence supports their introduction earlier in the disease course. However, therapies that alter the immune system, often used for long durations, may also promote carcinogenesis. As the population of patients with IBD grows older, with longer duration of chronic inflammation and longer exposure to immunosuppression, there is an increasing risk of cancer development. Many of these patients will require cancer treatment, including chemotherapy, radiation, hormonal therapy, and surgery. Many patients will require further treatment for their IBD. This review seeks to explore the characteristics and risks of cancer in patients with IBD, and to evaluate the limited data on patients with IBD and cancer, including management of IBD after a diagnosis of cancer, the effects of cancer treatment on IBD, and the effect of IBD and medications for IBD on cancer outcomes. In patients with inflammatory bowel disease (IBD), chronic inflammation is a major risk factor for the development of gastrointestinal malignancies. The pathogenesis of colitis-associated cancer is distinct from sporadic colorectal carcinoma and the critical molecular mechanisms underlying this process have yet to be elucidated. Patients with IBD have also been shown to be at increased risk of developing extra-intestinal malignancies. Medical therapies that diminish the mucosal inflammatory response represent the foundation of treatment in IBD, and recent evidence supports their introduction earlier in the disease course. However, therapies that alter the immune system, often used for long durations, may also promote carcinogenesis. As the population of patients with IBD grows older, with longer duration of chronic inflammation and longer exposure to immunosuppression, there is an increasing risk of cancer development. Many of these patients will require cancer treatment, including chemotherapy, radiation, hormonal therapy, and surgery. Many patients will require further treatment for their IBD. This review seeks to explore the characteristics and risks of cancer in patients with IBD, and to evaluate the limited data on patients with IBD and cancer, including management of IBD after a diagnosis of cancer, the effects of cancer treatment on IBD, and the effect of IBD and medications for IBD on cancer outcomes.
出处 《World Journal of Gastroenterology》 SCIE CAS 2016年第20期4794-4801,共8页 世界胃肠病学杂志(英文版)
关键词 INFLAMMATORY BOWEL disease CANCER ANTITUMOR NECROSIS factor IMMUNOSUPPRESSION Chemotherapy Radiation Inflammatory bowel disease Cancer Anti-tumor necrosis factor Immunosuppression Chemotherapy Radiation
  • 相关文献

参考文献62

  • 1Harry Sokol,Laurent Beaugerie,Marc Maynadié,David Laharie,Jean‐Louis Dupas,Bernard Flourié,Eric Lerebours,Laurent Peyrin‐Biroulet,Matthieu Allez,Tabassome Simon,Fabrice Carrat,Nicole Brousse.??Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease(J)Inflamm Bowel Dis . 2012 (11)
  • 2Angelamaria Rizzo,Francesco Pallone,Giovanni Monteleone,Massimo Claudio Fantini.Intestinal inflammation and colorectal cancer:A doubleedged sword?[J].World Journal of Gastroenterology,2011,17(26):3092-3100. 被引量:26
  • 3Ralph Francescone,Vivianty Hou,Sergei I. Grivennikov.??Cytokines, IBD, and Colitis-associated Cancer(J)Inflammatory Bowel Diseases . 2015 (2)
  • 4Thergiory Irrazábal,Antoaneta Belcheva,Stephen E. Girardin,Alberto Martin,Dana J. Philpott.??The Multifaceted Role of the Intestinal Microbiota in Colon Cancer(J)Molecular Cell . 2014 (2)
  • 5Takahiko Hamaguchi,Hiroki Wakabayashi,Akihiko Matsumine,Akihiro Sudo,Atsumasa Uchida.??TNF inhibitor suppresses bone metastasis in a breast cancer cell line(J)Biochemical and Biophysical Research Communications . 2011 (3)
  • 6Millie D. Long,Hans H. Herfarth,Clare A. Pipkin,Carol Q. Porter,Robert S. Sandler,Michael D. Kappelman.Increased Risk for Non-Melanoma Skin Cancer in Patients With Inflammatory Bowel Disease[J]. Clinical Gastroenterology and Hepatology . 2010 (3)
  • 7Pia Manninen,Anna-Liisa Karvonen,Johanna Laukkarinen,Petri Aitola,Heini Huhtala,Pekka Collin.??Colorectal cancer and cholangiocarcinoma in patients with primary sclerosing cholangitis and inflammatory bowel disease(J)Scandinavian Journal of Gastroenterology . 2014 (4)
  • 8Anthony Lopez,Morgane Mounier,Anne-Marie Bouvier,Fabrice Carrat,Marc Maynadié,Laurent Beaugerie,Laurent Peyrin-Biroulet.??Increased Risk of Acute Myeloid Leukemias and Myelodysplastic Syndromes in Patients Who Received Thiopurine Treatment for Inflammatory Bowel Disease(J)Clinical Gastroenterology and Hepatology . 2014
  • 9A. Bourrier,F. Carrat,J.‐F. Colombel,A.‐M. Bouvier,V. Abitbol,P. Marteau,J. Cosnes,T. Simon,L. Peyrin‐Biroulet,L. Beaugerie.??Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study(J)Aliment Pharmacol Ther . 2016 (2)
  • 10David S. Kotlyar,Mark T. Osterman,Robert H. Diamond,David Porter,Wojciech C. Blonski,Mariusz Wasik,Sami Sampat,Manuel Mendizabal,Ming V. Lin,Gary R. Lichtenstein.A Systematic Review of Factors That Contribute to Hepatosplenic T-Cell Lymphoma in Patients With Inflammatory Bowel Disease[J]. Clinical Gastroenterology and Hepatology . 2011 (1)

二级参考文献1

共引文献79

同被引文献232

引证文献34

二级引证文献164

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部